Physician profile
Christopher J Manuel
NPI 1801110127
$145,436.94
in general payments reported to CMS, 2019-2025
11 companies · $94K in 2025
The $94K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $382 · 2023: $283 · 2024: $50K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Travel and Lodging: $18K · Consulting Fee: $11K · Food and Beverage: $3,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,318.50 |
| Travel and Lodging | $17,830.05 |
| Consulting Fee | $11,250.00 |
| Food and Beverage | $3,174.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $143,913.16 | 2022-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $807.79 | 2021-2025 | Nuplazid |
| Sk Life Science, INC. | $124.93 | 2022 | |
| Avanir Pharmaceuticals, INC. | $107.23 | 2021 | |
| Convatec INC. | $105.81 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $91.48 | 2021 | |
| Sunovion Pharmaceuticals INC. | $89.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $88.75 | 2021 | |
| Sun Pharmaceutical Industries INC. | $60.46 | 2021 | |
| Janssen Scientific Affairs, LLC | $37.31 | 2024 | Xarelto |
| Sumitomo Pharma America, INC. | $10.65 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.